Human LXN (TCI) knockout HeLa cell line
Be the first to review this product! Submit a review
|
(0 Publication)
LXN KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and 8 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.
View Alternative Names
ECI, Endogenous carboxypeptidase inhibitor, LXN_HUMAN, Latexin, Latexin protein, MUM, Protein MUM, TCI, Tissue carboxypeptidase inhibitor
- Sanger seq
Unknown
Sanger Sequencing - Human LXN (TCI) knockout HeLa cell line (AB265921)
Allele-1 : 8 bp deletion in exon 1.
- Sanger seq
Unknown
Sanger Sequencing - Human LXN (TCI) knockout HeLa cell line (AB265921)
Allele-2 : 7 bp deletion in exon 1.
- Sanger seq
Unknown
Sanger Sequencing - Human LXN (TCI) knockout HeLa cell line (AB265921)
Allele-3 : Insertion of the selection cassette in exon 1.
Product details
Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling procedures
Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LXN influences cell proliferation and differentiation. It participates in cellular protection mechanisms against enzymatic damage and balances protease and anti-protease activities in tissues. Although not part of a large complex LXN impacts various cellular events through its protease inhibitor function making it important in tissue homeostasis. Studies suggest its importance in maintaining cell viability and regulating cellular stress responses.
Pathways
LXN associates with pathways linked to inflammation and tissue remodeling with particular emphasis on the protease-antiprotease balance. LXN acts within the kallikrein-kinin system and relates to proteins such as carboxypeptidase A1 which it directly inhibits. Its modulation of these pathways is essential for normal physiological responses and protective mechanisms against tissue damage.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Target data
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com